Closed Research Teams
Recent submissions
-
High-dimensional functional phenotyping of preclinical human CAR T cells using mass cytometry.
Here, we present a comprehensive protocol for the generation and functional characterization of chimeric antigen receptor (CAR) T cells and their products by mass cytometry in a reproducible and scalable manner. We describe ... -
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
(WILEY, 2022-08-01)Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis ... -
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
(AMER ASSOC CANCER RESEARCH, 2013-08-05)PURPOSE: To provide rationale for using phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathway inhibitors to treat rhabdomyosarcomas, a major cause of pediatric and adolescent cancer deaths. ... -
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
(FUTURE MEDICINE LTD, 2021-11-01)Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy results in an initial testosterone flare, and ... -
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
(ELSEVIER SCIENCE INC, 2022-01-29)BACKGROUND: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 ... -
Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents.
(2013-01-01)The G-protein coupled C-X-C chemokine receptor type 4 (CXCR4) is highly overexpressed in a range of cancers and is therefore an excellent biomarker for cancer imaging. To this end targeted iron oxide nanoparticles were ... -
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.
(NATURE PORTFOLIO, 2022-01-01)Genetic intra-tumour heterogeneity fuels clonal evolution, but our understanding of clinically relevant clonal dynamics remain limited. We investigated spatial and temporal features of clonal diversification in clear cell ... -
Interobserver variability in target volume delineation for CT/MRI simulation and MRI-guided adaptive radiotherapy in rectal cancer.
(BRITISH INST RADIOLOGY, 2021-12-01)OBJECTIVES: Quantify target volume delineation uncertainty for CT/MRI simulation and MRI-guided adaptive radiotherapy in rectal cancer. Define optimal imaging sequences for target delineation. METHODS: Six experienced ... -
Impact of Pelvic Radiation Therapy for Prostate Cancer on Global Metabolic Profiles and Microbiota-Driven Gastrointestinal Late Side Effects: A Longitudinal Observational Study.
(ELSEVIER SCIENCE INC, 2021-12-01)PURPOSE: Radiation therapy to the prostate and pelvic lymph nodes (PLNRT) is part of the curative treatment of high-risk prostate cancer. Yet, the broader influence of radiation therapy on patient physiology is poorly ... -
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-03-10)PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic ... -
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
(ELSEVIER SCIENCE INC, 2021-10-19)BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and ... -
PTEN inactivation has distinct effects on the signalling properties of EGFR and MET and their response to kinase inhibitors
(Institute of Cancer Research (University Of London), 2020-09-30)Receptor tyrosine kinases (RTKs) are a family of cell-surface receptors that play a major role in regulating pro-proliferative and pro-survival signalling pathways, such as the Phosphoinositide 3-kinase (PI3K/Akt) pathway. ... -
The molecular characterisation of MET addiction in lung cancer
(Institute of Cancer Research (University Of London), 2020-08-31)The traditional classification of lung cancer has been radically altered with increased understanding of the molecular alterations and genomic biomarkers that drive the development of the disease. Whilst molecularly targeted ... -
Circulating cell-free DNA methylation analysis of metastatic prostate cancer
(Institute of Cancer Research (University Of London), 2020-03-31)Introduction; Materials and methods; Deciphering global plasma DNA methylation variance in metastatic prostate cancer; Implementation of a methylation signature for tracking and detection of prostate cancer in plasma; ... -
Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
(BMC, 2021-06-05)BACKGROUND: Resistance to DNA damaging chemotherapies leads to cancer treatment failure and poor patient prognosis. We investigated how genomic distribution of accessible chromatin sites is altered during acquisition of ... -
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
Background Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse ... -
Magnetic resonance image guided adaptive radiotherapy for gynaecological and rectal cancer
(Institute of Cancer Research (University Of London), 2020-11-30)Multiple challenges exist in radiotherapy for gynaecological and rectal cancer. These lead to uncertainty and error in dose delivered to the tumour target and organs at risk (OARs). Adequate planning target volume (PTV) ... -
Investigating the molecular mechanisms of fraction size sensitivity in irradiated cells
(Institute of Cancer Research (University Of London), 2020-09-30)Fractionated radiotherapy is used clinically when it spares healthy tissue relative to the cancer; the healthy tissue is described as more fraction size sensitive. However, a molecular understanding of the mechanisms that ... -
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
(AMER MEDICAL ASSOC, 2021-04-01)IMPORTANCE: Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies ... -
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
(BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Endogenous retroviruses (ERVs) play a role in a variety of biological processes, including embryogenesis and cancer. DNA methyltransferase inhibitors (DNMTi)-induced ERV expression triggers interferon responses ...
RSS 1.0